Concert Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Concert Pharmaceuticals, Inc.
5 Talking Points As Sun's Cequa Hits Home Turf And There's Restasis
Cequa arrives in India, almost four years post US debut with Sun deploying what has generally been perceived as the text-book launch approach of foreign firms in the country. Scrip delves into the market dynamics in a segment where AbbVie's blockbuster Restasis is well entrenched.
10 Approvals To Look Out For In Q2
The second quarter has already seen the approval of Gamida Cell’s cell therapy Omisirge, and with the help of Biomedtracker, Scrip highlights 10 of the more interesting new drug approvals due in the next three months.
India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023
India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. In Vivo's sister publication Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023.
Sun Eyes Big Stage For Concert’s Alopecia Asset
Sun outlines contours of path ahead for deuruxolitinib, which came to it via the recent $576m Concert deal and pits it against Eli Lilly's Olumiant and Pfizer's investigational candidate ritlecitinib. The Indian firm is believed to have had the JAK 1/2 inhibitor on its radar since August last year.
Drug Discovery Technologies
- Natural Products
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Concert Pharmaceuticals Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.